Advenchen Laboratories

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
2Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
Aurora B / FGFR / VEGFR (multi-kinase)Small molecule
Non-Small Cell Lung CancerSmall Cell Lung Cancer
Phase 3
VEGFR2Small molecule
Non-Small Cell Lung CancerHepatocellular Carcinoma

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
July 2027 (1)
ApatinibPhase 2Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk
Est. primary completion 2027-07 · NCT07682272 · CT.gov ↗
What to watch
December 2027 (1)
AL8326Phase 2Small Cell Lung Cancer, Renal Cell Carcinoma (RCC), Non-Small Cell Lung
Est. primary completion 2027-12 · NCT05363280 · CT.gov ↗
What to watch
2028 (1)
July 2028 (1)
AL8326Phase 3Small Cell Lung Carcinoma
Est. primary completion 2028-07 · NCT06247605 · CT.gov ↗
What to watch
2029 (1)
November 2029 (1)
AL8326Phase 1/2Solid Tumor
Est. primary completion 2029-11-07 · NCT07392736 · CT.gov ↗
What to watch
2030 (1)
September 2030 (1)
AL8326Phase 1/2Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
Est. primary completion 2030-09-01 · NCT07811232 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 October 2026Filing submittedApatinibRivoceranib NDA resubmitted to the FDA after July 2026 CRL
US, FDA · Elevar Therapeutics, Inc. · Source ↗
10 July 2026Complete response letterApatinibFDA issues complete response letter for rivoceranib + camrelizumab NDA (first-line uHCC)
US, FDA · Elevar Therapeutics, Inc. · Source ↗

Financial reports

No financial reports recorded.